Literature DB >> 17932121

Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells.

C Angelozzi1, F Borgo, F D Tiziano, A Martella, G Neri, C Brahe.   

Abstract

Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder caused by homozygous absence of the survival motor neuron gene (SMN1). All patients have at least one, usually two to four copies of the related SMN2 gene which, however, produce insufficient levels of functional SMN protein due to the exclusion of exon 7 in the majority of SMN2 transcripts. Here, we show that salbutamol, a beta2-adrenoceptor agonist, determines a rapid and significant increase in SMN2-full length mRNA and SMN protein in SMA fibroblasts, predominantly by promoting exon 7 inclusion in SMN2 transcripts. These data, together with previous clinical findings, provide a strong rationale to investigate further the clinical efficacy of salbutamol in SMA patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17932121     DOI: 10.1136/jmg.2007.051177

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  31 in total

1.  SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR.

Authors:  Francesco Danilo Tiziano; Anna Maria Pinto; Stefania Fiori; Rosa Lomastro; Sonia Messina; Claudio Bruno; Antonella Pini; Marika Pane; Adele D'Amico; Alessandro Ghezzo; Enrico Bertini; Eugenio Mercuri; Giovanni Neri; Christina Brahe
Journal:  Eur J Hum Genet       Date:  2010-01       Impact factor: 4.246

2.  Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: clues from a biomarker study.

Authors:  Francesco D Tiziano; Rosa Lomastro; Lorena Di Pietro; Maria Barbara Pasanisi; Stefania Fiori; Carla Angelozzi; Emanuela Abiusi; Corrado Angelini; Gianni Sorarù; Alessandra Gaiani; Tiziana Mongini; Liliana Vercelli; Gessica Vasco; Giuseppe Vita; Gian Luca Vita; Sonia Messina; Luisa Politano; Luigia Passamano; Grazia Di Gregorio; Cristina Montomoli; Chiara Orsi; Angela Campanella; Renato Mantegazza; Lucia Morandi
Journal:  Eur J Hum Genet       Date:  2012-10-17       Impact factor: 4.246

Review 3.  Small Molecules in Development for the Treatment of Spinal Muscular Atrophy.

Authors:  Alyssa N Calder; Elliot J Androphy; Kevin J Hodgetts
Journal:  J Med Chem       Date:  2016-08-16       Impact factor: 7.446

4.  Drug treatment for spinal muscular atrophy types II and III.

Authors:  Renske I Wadman; W Ludo van der Pol; Wendy Mj Bosboom; Fay-Lynn Asselman; Leonard H van den Berg; Susan T Iannaccone; Alexander Fje Vrancken
Journal:  Cochrane Database Syst Rev       Date:  2020-01-06

5.  CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy.

Authors:  Marco A Passini; Jie Bu; Eric M Roskelley; Amy M Richards; S Pablo Sardi; Catherine R O'Riordan; Katherine W Klinger; Lamya S Shihabuddin; Seng H Cheng
Journal:  J Clin Invest       Date:  2010-03-15       Impact factor: 14.808

6.  Treatment of spinal muscolar atrophy with intrathecal mesenchymal cells.

Authors:  Marino Andolina
Journal:  Int J Stem Cells       Date:  2012-05       Impact factor: 2.500

Review 7.  SMN-inducing compounds for the treatment of spinal muscular atrophy.

Authors:  Monique A Lorson; Christian L Lorson
Journal:  Future Med Chem       Date:  2012-10       Impact factor: 3.808

8.  Emerging treatment options for spinal muscular atrophy.

Authors:  Barrington G Burnett; Thomas O Crawford; Charlotte J Sumner
Journal:  Curr Treat Options Neurol       Date:  2009-03       Impact factor: 3.598

9.  Regulation of SMN protein stability.

Authors:  Barrington G Burnett; Eric Muñoz; Animesh Tandon; Deborah Y Kwon; Charlotte J Sumner; Kenneth H Fischbeck
Journal:  Mol Cell Biol       Date:  2008-12-22       Impact factor: 4.272

Review 10.  Spinal muscular atrophy.

Authors:  Maryam Oskoui; Petra Kaufmann
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.